Hernández-López, Rubí
,
Lorincz, Attila T. http://orcid.org/0000-0001-7617-4355
Torres-Ibarra, Leticia
Reuter, Caroline
Scibior-Bentkowska, Dorota
Warman, Rhian
Nedjai, Belinda
Mendiola-Pastrana, Indira
León-Maldonado, Leith
Rivera-Paredez, Berenice
Ramírez-Palacios, Paula
Lazcano-Ponce, Eduardo
Cuzick, Jack
Salmerón, Jorge
Funding for this research was provided by:
Instituto Mexicano del Seguro Social
Secretaría de Salud
Consejo Nacional de Ciencia y Tecnología
Cancer Research UK (C569/A10404)
Instituto Nacional de Salud Publica
Article History
Received: 10 April 2019
Accepted: 12 September 2019
First Online: 12 October 2019
Ethics approval and consent to participate
: The FRIDA study was reviewed and approved by the research and ethics committees of the Instituto Nacional de Salud Pública (INSP) (1094), Mexican regulatory agency COFEPRIS (CAS/OR/01/CAS/123300410C0044-3578/2012), and Tlaxcala State Ministry of Health (SSET) (SS.DECI-OI-13/12). The purpose and procedures of the study were explained to all participants, and informed verbal consent was obtained. The FRIDA Study design and management were supported by a group of principal investigators, steering committee, and subcommittees including molecular triage, quality control of cytology and pathology, and safety and case management.
: JS and ELP have received funding for research projects from Qiagen, Roche, Beckton Dickinson, Gen-Probe, DICIPA, and Arbor Vita. The other authors declare no competing interests.